Overview
Rho is a contract research organization that provides end-to-end services for developing and gaining regulatory approval for drugs, biologics, and medical devices. It supports planning and executing clinical development, regulatory strategy, and marketing submissions, guiding projects from program strategy through NDAs, BLAs, and MAAs. An integrated team handles decentralized clinical trials and has infectious-disease programs, combining trial design, data management, and regulatory insight to move products toward approval. Its goal is to help clients bring products to market efficiently by navigating regulatory requirements and streamlining development and submission processes.
Work here?Claim your company
Simplify's take
What believers are saying
- Rho won NIH-NIAID autoimmune disease support work, reinforcing its government credibility.
- Rho added Andrew Feigin, MD as Chief Medical Officer, strengthening neuroscience execution.
- Rho launched incorporation and Stripe Atlas partnerships in 2026, signaling broader founder reach.
What critics are saying
- RHO Federal Systems Division’s obligations fell 8.8% to $10.5M through October 2026.
- The $40.1M autoimmune ADSCCC contract ends January 31, 2027, pressuring renewals.
- Federal concentration creates an existential risk if HHS shifts awards to larger CROs.
What makes Rho unique
- Rho blends CRO execution with federal contracting and commercial drug development.
- Rho’s 25-year federal arena experience supports NIH, BARDA, and NIAID programs.
- Rho emphasizes decentralized and virtual trials across infectious disease, pain, and neurology.
Help us improve and share your feedback! Did you find this helpful?